Clinical impact of contact force and its regional variability on efficiency and effectiveness of pulmonary vein isolation for atrial fibrillation.

Journal of cardiology

PubMedID: 26603325

Sotomi Y, Inoue K, Kikkawa T, Tanaka K, Toyoshima Y, Oka T, Tanaka N, Orihara Y, Iwakura K, Sakata Y, Fujii K. Clinical impact of contact force and its regional variability on efficiency and effectiveness of pulmonary vein isolation for atrial fibrillation. J Cardiol. 2016;.
BACKGROUND
The purpose of this study is to analyze the impact of average contact force (CF) and its regional variability during pulmonary vein isolation (PVI) for atrial fibrillation (AF) on periprocedural parameters and midterm outcome.

METHODS
This retrospective cohort study enrolled 57 drug-refractory AF patients who underwent initial PVI for AF using an open-irrigated CF catheter (SmartTouch Thermocool, Biosense Webster, Diamond Bar, CA, USA). Thirty patients were assigned to a lower CF (LCF) group (average CF=10g) and 27 patients to a higher CF (HCF) group (average CF>10g). The relationship between CF and clinical outcome was analyzed.

RESULTS
Patients were followed-up for 317±57 days after PVI. The CF was 8.1±1.3g in the LCF group and 12.4±1.5g in the HCF group. Higher average CF was associated with shorter ablation time (28±6min vs. 36±9min, p=0.0002) and lower radiofrequency energy delivery (79±18 vs. 99±26, p=0.0016) for PVI. The rate of acute PV reconnection (APVR) was similar in both groups (LCF group 60% vs. HCF group 44%, p=0.36). Four patients (13%) in the LCF group and nine patients (33%) in the HCF group experienced AF-recurrence. Average CF did not impact on AF-recurrence during midterm clinical outcome (p=0.09 by log-rank test). In the non-recurrence group (n=44), average CF was higher at left posterosuperior PV and right anteroinferior PV than that in the recurrence group (n=13) (p=0.012 and p=0.004, respectively).

CONCLUSIONS
Higher average CF decreased ablation time and radiofrequency energy delivery for PVI, but did not decrease APVR rate or improve midterm clinical outcome.